CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

CD19 与 BCMA 靶向 CAR-T 细胞治疗中输注前宿主骨髓易感性：克隆性造血、血液毒性与治疗相关髓系肿瘤

Pre-Infusion Host-Marrow Vulnerability in CD19- and BCMA-Directed CAR T-Cell Therapy: Clonal Hematopoiesis, Hematotoxicity, and Therapy-Related Myeloi

将 B 细胞与浆细胞靶向从肿瘤学转化至自身免疫：模式、定量桥接与开发路线图

Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.

基于可溶性抗原的 PET/MR 对 BCMA CAR+ T 细胞淋巴瘤的特异性检测

Soluble-Antigen-Based PET/MR for the Specific Detection of BCMA CAR+ T-Cell Lymphoma.

CXCR4 修饰通过改善 B 细胞恶性肿瘤的肿瘤追踪与骨髓归巢增强 CAR-T 疗效

CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies.

早期鞘内注射地塞米松和甲氨蝶呤作为 CAR-T 细胞治疗后免疫效应细胞相关神经毒性综合征的有效方法

Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell

我们的数据提示，早期给予 IDM 可能有助于快速缓解 CAR-T 细胞治疗后的重度或类固醇难治性 ICANS，这可能为这些患者的后续治疗创造机会。

基于 BAFF 的三功能 T 细胞衔接器触发针对 B 细胞恶性肿瘤的强效抗肿瘤免疫

BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies.

白细胞介素-6 的关联：认识 CAR-T 细胞治疗后的巨细胞病毒再激活

The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.

CAR-T 细胞治疗实体瘤的挑战与进展

The challenges and progress of CAR-T cell therapy in the treatment of solid tumors.

BCMA CAR-T 诱导慢性淋巴细胞白血病同步转化的浆母细胞淋巴瘤完全持久缓解：病例报告与文献综述

BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report an